GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The compan… Read more
GeneDx Holdings Corp. (WGS) - Total Assets
Latest total assets as of September 2025: $493.90 Million USD
Based on the latest financial reports, GeneDx Holdings Corp. (WGS) holds total assets worth $493.90 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GeneDx Holdings Corp. - Total Assets Trend (2020–2024)
This chart illustrates how GeneDx Holdings Corp.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GeneDx Holdings Corp. - Asset Composition Analysis
Current Asset Composition (December 2024)
GeneDx Holdings Corp.'s total assets of $493.90 Million consist of 47.2% current assets and 52.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.3% |
| Accounts Receivable | $37.63 Million | 9.0% |
| Inventory | $10.65 Million | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $158.60 Million | 37.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how GeneDx Holdings Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GeneDx Holdings Corp.'s current assets represent 47.2% of total assets in 2024, a decrease from 69.2% in 2020.
- Cash Position: Cash and equivalents constituted 20.3% of total assets in 2024, down from 43.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 37.8% of total assets.
GeneDx Holdings Corp. Competitors by Total Assets
Key competitors of GeneDx Holdings Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
GeneDx Holdings Corp. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - GeneDx Holdings Corp. generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - GeneDx Holdings Corp. is currently not profitable relative to its asset base.
GeneDx Holdings Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.71 | 2.41 | 2.37 |
| Quick Ratio | 2.59 | 2.27 | 2.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $149.96 Million | $ 108.67 Million | $ 100.67 Million |
GeneDx Holdings Corp. - Advanced Valuation Insights
This section examines the relationship between GeneDx Holdings Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.92 |
| Latest Market Cap to Assets Ratio | 3.73 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | $419.38 Million |
| Market Capitalization | $1.56 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values GeneDx Holdings Corp.'s assets at a significant premium ( 3.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: GeneDx Holdings Corp.'s assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for GeneDx Holdings Corp. (2020–2024)
The table below shows the annual total assets of GeneDx Holdings Corp. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $419.38 Million | +0.15% |
| 2023-12-31 | $418.76 Million | -23.20% |
| 2022-12-31 | $545.26 Million | -1.59% |
| 2021-12-31 | $554.09 Million | +120.19% |
| 2020-12-31 | $251.64 Million | -- |